Anlotinib
- Generic Name
- Anlotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22FN3O3
- CAS Number
- 1058156-90-3
- Unique Ingredient Identifier
- GKF8S4C432
- Background
Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.
- Indication
用于治疗非小细胞肺癌、结直肠癌、肾癌、软组织肉瘤、甲状腺癌、胃癌等。
用于无法手术的局部晚期或转移性甲状腺髓样癌患者的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin
- Conditions
- Interventions
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2018-09-17
- Lead Sponsor
- Lingyu Luo
- Target Recruit Count
- 62
- Registration Number
- NCT03671538
Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2021-09-14
- Target Recruit Count
- 20
- Registration Number
- NCT03618238
- Locations
- 🇨🇳
Xinhua Hospital, Shanghai, China
Phase I Study of the Combination of Anlotinib With Gefitinib
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2018-07-26
- Target Recruit Count
- 9
- Registration Number
- NCT03602027
A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
- Conditions
- Interventions
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2018-07-19
- Target Recruit Count
- 51
- Registration Number
- NCT03591666
- Locations
- 🇨🇳
Shanghai ninth people's hospital, Shanghai, Shanghai, China
Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel
- Conditions
- Interventions
- First Posted Date
- 2018-06-25
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT03566576
Study of Anlotinib in Patients With Primary Malignant Bone Tumors
- First Posted Date
- 2018-05-17
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT03527888
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Beijing Jishuitan Hospital, Beijing, Beijing, China
A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3
- First Posted Date
- 2018-03-08
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03457844
- Locations
- 🇨🇳
Yihebali Chi, Beijing, Beijing, China
Anlotinib and Irinotecan for Ewing Sarcoma
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 47
- Registration Number
- NCT03416517
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, China
Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2019-05-16
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT03059797
- Locations
- 🇨🇳
The 307th Hospital of Chinese People's Liberation Army, Beijing, Beijing, China
🇨🇳Guangdong General Hospital, Guangzhou, Guangdong, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2019-05-22
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT02825563
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.